Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).
J Med Chem
; 56(6): 2218-34, 2013 Mar 28.
Article
in En
| MEDLINE
| ID: mdl-23394126
ABSTRACT
A series of novel, highly potent, selective, and ATP-competitive mammalian target of rapamycin (mTOR) inhibitors based on a benzoxazepine scaffold have been identified. Lead optimization resulted in the discovery of inhibitors with low nanomolar activity and greater than 1000-fold selectivity over the closely related PI3K kinases. Compound 28 (XL388) inhibited cellular phosphorylation of mTOR complex 1 (p-p70S6K, pS6, and p-4E-BP1) and mTOR complex 2 (pAKT (S473)) substrates. Furthermore, this compound displayed good pharmacokinetics and oral exposure in multiple species with moderate bioavailability. Oral administration of compound 28 to athymic nude mice implanted with human tumor xenografts afforded significant and dose-dependent antitumor activity.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Binding, Competitive
/
Adenosine Triphosphate
/
Protein Kinase Inhibitors
/
Drug Discovery
/
TOR Serine-Threonine Kinases
Limits:
Animals
/
Female
/
Humans
/
Male
Language:
En
Journal:
J Med Chem
Journal subject:
QUIMICA
Year:
2013
Document type:
Article
Affiliation country:
United States